FindTrial
Sign In

Clinical and Epidemiological Study of EGFR Mutation and EML4-ALK Fusion Gene Among Indian Patients with Adenocarcinoma Lung

Clinical and Epidemiological Study of EGFR Mutation and EML4-ALK Fusion Gene Among Indian Patients with Adenocarcinoma Lung

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2012/04/002589
Enrollment
500
Registered
2012-04-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Non Small Cell Lung Cancer (NSCLC)

Interventions

None listed

Sponsors

Pfizer India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients known as having an adenocarcinoma histology of NSCLC, already tested for EGFR mutational status and treated over the last 2 years will be considered for this study.

Exclusion criteria

Exclusion criteria: Non-adenocarcinoma histology of NSCLC

Design outcomes

Primary

MeasureTime frame
Evaluation of the prevalence of EGFR and EML4-ALK fusion in Indian NSCLC (adenocarcinoma) patient populationTimepoint: Single Time-point. As the study involves retrospective analysis of available slides/tissue blocks at trial sites, the collection of individual sample will be done at a single time-point and analysis also will be for a single time-point.—

Secondary

MeasureTime frame
To evaluate the association of EGFR and EML4-ALK fusion with clinical and pathologic parameters of NSCLC (adenocarcinoma) and patient characteristics Timepoint: Single Time-point—

Countries

India

Contacts

Public ContactDr D C Doval

Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Delhi

dcdoval@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026